Last updated: March 24, 2026
What is NDC 00904-6986?
NDC 00904-6986 corresponds to a branded or generic drug product within healthcare inventory, typically used for specific indications. The National Drug Code (NDC) identifies the package size, dosage form, and manufacturer details.
Note: Exact product details are needed to provide a precise analysis, but the following considers typical market dynamics for products within similar categories.
Market Size and Competitive Landscape
Current Market Size
Based on recent data, the total U.S. market for drugs within its therapeutic class is estimated at approximately $X billion. For products with similar indications, annual prescriptions number approximately Y million, with a per-unit wholesale acquisition cost (WAC) averaging $Z.
Key Competitors
The market features:
- Brand-name competitors: Dominant in initial launch periods, with higher prices and marketing support.
- Generic competitors: Increased market share since patent expiry or exclusivity end, typically priced 40-70% below brand equivalents.
- Alternative therapies: Non-pharmacological options or off-label uses affecting demand dynamics.
Market Trends
- Growth rate: Historical compound annual growth rate (CAGR) of X% over the past five years.
- Regulatory environment: Patent expirations or new approvals that influence market shares.
- Insurance coverage: Reimbursement policies can impact accessibility and sales volume.
Price Projections
Short-term (Next 1-2 Years)
- Wholesale acquisition cost (WAC): Currently around $A per unit.
- Pricing trends: Slight decrease influenced by increased generic competition and payer negotiations, estimated at -Y% annually.
- Market volume: Expected to stabilize or slightly decline as off-label or alternative therapies emerge.
Long-term (3-5 Years)
- Price reduction: Projected further decrease of -Z% due to market saturation.
- Value-based pricing: Payers' increasing resistance to high-cost drugs may push prices downward.
- Potential premium: If new formulations or indications are approved, prices could temporarily increase by X%.
Projections Table
| Year |
Estimated WAC per Unit |
Projected Market Share |
Estimated Revenue |
| 2023 |
$A |
50% |
$M |
| 2024 |
$A - Y% |
45% |
$M - N% |
| 2025 |
$A - Z% |
40% |
$M - N% |
Values are placeholders pending actual data.
Policy and Reimbursement Factors
- Pricing regulations: Reimbursement caps and price control legislation may limit genuine price increases.
- Negotiation leverage: Market exclusivity status influences pricing power.
- Patient assistance programs: Can impact effective patient costs and demand elasticity.
Supply Chain and Manufacturing Considerations
- Manufacturing costs: Driven by raw material prices, quality standards, and scale.
- Supply disruptions: Can lead to price instability, especially if reliant on specific suppliers.
Key Takeaways
- The product faces an increasingly competitive landscape with price erosion expected over the next 3-5 years.
- Market size remains steady due to consistent demand but is susceptible to shifts in treatment guidelines.
- Price projections suggest a modest decline in WAC per unit, influenced by generic competition and payer negotiations.
- Potential for temporary price increases linked to innovative formulations or new indications.
- Regulatory, reimbursement, and supply chain factors will significantly influence actual pricing trends.
FAQs
What factors most influence the price of this drug?
Reimbursement policies, patent status, market competition, and manufacturing costs.
How likely is price stabilization in the next 2 years?
Moderate, contingent on market entry of generics and payer negotiations.
Can new indications significantly change pricing?
Yes, if approved, new indications can justify higher prices and market expansion.
What is the regulatory outlook?
Pending FDA reviews and legislative changes may affect approval timing and pricing flexibility.
How does supply chain stability affect pricing?
Disruptions can increase costs and reduce supply, leading to price volatility.
References
- U.S. Food and Drug Administration. (2022). Drug Approvals and Regulatory Guidance.
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- CMS. (2022). Reimbursement and Pricing Policies.
- GoodRx Research. (2022). Biopharmaceutical Pricing Trends.
- EvaluatePharma. (2022). Global Pharmaceutical Market Outlook.
